UCSF to Receive Tobacco Papers, Funding to Improve Public Access to the Documents
Update: Another cigarette manufacturer, Lorillard, Inc., has joined the consent order – four major tobacco companies are now involved in the agreement. Lorillard will pay $650,000 to the federal district court to improve public access to internal documents, bringing to $6.9 million the sum being paid by the companies. The court will provide the money to the UCSF Legacy Library.
The U.S. Department of Justice filed a proposed consent order today with a federal district court that finalizes requirements for three major tobacco companies to make internal documents public in accordance with an earlier ruling that the companies violated the Racketeer Influenced and Corrupt Organizations Act. The documents will be archived in UCSF’s Legacy Tobacco Documents Library (LTDL).
The order, once approved by the court, will be part of the remedy phase of the largest civil racketeering case in the history of the United States.
The order specifies that the companies provide $6.25 million to the court to improve free public access to the documents via the Internet. The court will provide this money to the UCSF Legacy Library for this purpose. The order also specifies how the companies are to index the documents.
The UCSF Legacy Library, first launched in 2000 with a major gift from the Washington, D.C.-based American Legacy Foundation, now has 13.7 million documents (79 million pages) released as a result of litigation against the major tobacco companies related to their advertising, manufacturing, marketing, sales, political, public relations and scientific activities.
An earlier order by Federal Judge Gladys Kessler, filed in U.S. District Court for the District of Columbia in Washington, D.C., requires the tobacco companies to continue to release documents through 2021. The UCSF Legacy Library has been growing by about 700,000 documents in each of the past three years.
Each month, the Legacy Library is used by an average of 16,000 academic researchers, tobacco control advocates, lawyers, journalists and students internationally who view an average of 227,000 pages. Last year, visitors came from 190 different countries to use it. Close to 600 peer-reviewed journal articles and 130 other publications, including government reports, books and newspaper articles based on research at the library have been published. The new funds will allow all of that information to be digitized for early access online.
“These funds will allow us to substantially improve the way investigators, the media and the public are able to research how tobacco companies produce, price and market their products, as well as protect their political interests globally,” said Kim Klausner, UCSF Industry Documents Digital Library Manager.
Sam Hawgood, MBBS, dean of the UCSF School of Medicine and vice chancellor for medical affairs, said the University is “gratified that the court recognizes the important contributions that UCSF has made, and will continue to make, to global public health through the Legacy Tobacco Documents Library. Making these documents freely available to everyone is an important element of UCSF’s contribution as a public university,” he said.
The defendant tobacco companies that agreed to the proposed court order are Philip Morris USA, Inc, Altria Group, and RJ Reynolds Tobacco Company. The proposed consent order is subject to court approval and is not final until it is signed and entered by the court.
“Research based on the documents has provided a unique insight into how the tobacco industry manipulates scientific and political processes and engineers its products and marketing to maximize its sales,” said Stanton A. Glantz, PhD, UCSF professor of medicine and director of the Center for Tobacco Control Research and Education at UCSF. “By revealing the industry’s behind-the-scenes strategies and involvement, this understanding has transformed public health from city councils to the United Nations.”
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.